Evidence map›Paper›PMID 35484644›Full record

ArticleClinical and molecular hepatology2022

Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial.

Ju Hee Oh, Dae Won Jun, Hye Young Kim, Seung Min Lee, Eileen L Yoon, Jungwook Hwang, Jung Hwan Park, Hanbi Lee, Wankyu Kim, Hyunsung Kim

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and molecular hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Discovery of Nine Dipeptidyl Peptidase-4 Inhibitors fromMolecules (Basel, Switzerland) · 2024
    Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Ju Hee OhDepartment of Translational Medicine, Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, Korea.
Dae Won JunDepartment of Translational Medicine, Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, Korea.
Hye Young KimDepartment of Translational Medicine, Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, Korea.
Seung Min LeeDepartment of Translational Medicine, Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, Korea.
Eileen L YoonDepartment of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
Jungwook HwangDepartment of Medical genetic, Hanyang University College of Medicine, Seoul, Korea.
Jung Hwan ParkDepartment of Endocrinology, Hanyang University College of Medicine, Seoul, Korea.
Hanbi LeeDepartment of Life Sciences, College of Natural Science, Ewha Womans University, Seoul, Korea.
Wankyu KimDepartment of Life Sciences, College of Natural Science, Ewha Womans University, Seoul, Korea.
Hyunsung KimDepartment of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
Hanyang University · KREwha Womans University · KRHanyang University Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsWe aimed to define an optimal target population and drug-specific biomarkers that may predict dipeptidyl peptidase (DPP)-4 inhibitor responses in non-alcoholic fatty liver disease (NAFLD).

methodsAn exploration study (study I) was performed using three different NAFLD models (basket study design; high-fat diet [HFD], methionine choline-deficient diet [MCD], and high-cholesterol Western diet [WD] models). RNA transcriptome analysis was performed on pre-studied liver tissues to identify biomarkers that could predict the response to DPP-4 inhibitors. In the validation study (study II), the HFD-induced NAFLD model was divided into high and low hepatic insulin-like growth factor binding protein 1 (Igfbp-1) groups based on the pre-study liver biopsy.

resultsDPP-4 inhibitor attenuated the NAFLD activity score and fibrosis stage in the HFD model but not in the WD and MCD models. The overall response rate was 19% across the modified basket NAFLD trial and 42%, 25%, and 0% in the HFD, WD, and MCD models. Hepatic Igfbp-1 expression was higher in the responder group than in the non-responder group in pre-study biopsy samples. In contrast, hepatic Igfbp-1 expression was lower in the responder group than in the non-responder group in the end-study biopsy samples. DPP-4 inhibitor response rates were 83% and 17% in the baseline hepatic high Igfbp-1 and low Igfbp-1 groups, respectively. Hepatic messenger RNA Igfbp-1 expression was positively correlated with serum IGFBP-1 levels.

conclusionThe DPP-4 inhibitor response was higher in the HFD phenotype and pre-treatment levels of hepatic or serum IGFBP-1 were high.

Indexed as

Dipeptidyl-Peptidase IV InhibitorsNon-alcoholic Fatty Liver DiseaseAnimalsBiomarkersDiet, High-FatDipeptidyl-Peptidases and Tripeptidyl-PeptidasesHumansHypoglycemic AgentsInsulin-Like Growth Factor Binding Protein 1LiverMiceBiomarkersDipeptidyl-Peptidase IV InhibitorsDipeptidyl-Peptidases and Tripeptidyl-PeptidasesHypoglycemic AgentsInsulin-Like Growth Factor Binding Protein 1BiomarkerBiopsyDipeptidyl peptidase 4 inhibitorInsulin-like growth factor binding protein 1Nonalcoholic fatty liver disease

Identifiers

PMID35484644
PMCPMC9293604
OpenAlexW4225014346

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.